These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 17121795)
41. Identification of overlapping class I and class II H-2d-restricted T cell determinants of influenza virus N1 neuraminidase that require infectious virus for presentation. Wysocka M; Eisenlohr LC; Otvos L; Horowitz D; Yewdell JW; Bennink JR; Hackett CJ Virology; 1994 May; 201(1):86-94. PubMed ID: 7513927 [TBL] [Abstract][Full Text] [Related]
42. Increased Immunogenicity of Full-Length Protein Antigens through Sortase-Mediated Coupling on the PapMV Vaccine Platform. Laliberté-Gagné MÈ; Bolduc M; Thérien A; Garneau C; Casault P; Savard P; Estaquier J; Leclerc D Vaccines (Basel); 2019 Jun; 7(2):. PubMed ID: 31212772 [No Abstract] [Full Text] [Related]
43. Engineering of papaya mosaic virus (PapMV) nanoparticles through fusion of the HA11 peptide to several putative surface-exposed sites. Rioux G; Babin C; Majeau N; Leclerc D PLoS One; 2012; 7(2):e31925. PubMed ID: 22363771 [TBL] [Abstract][Full Text] [Related]
45. Antagonism or synergism between papaya ringspot virus and papaya mosaic virus in Carica papaya is determined by their order of infection. Chávez-Calvillo G; Contreras-Paredes CA; Mora-Macias J; Noa-Carrazana JC; Serrano-Rubio AA; Dinkova TD; Carrillo-Tripp M; Silva-Rosales L Virology; 2016 Feb; 489():179-91. PubMed ID: 26765969 [TBL] [Abstract][Full Text] [Related]
46. TCR-Mediated internalization of peptide-MHC complexes acquired by T cells. Huang JF; Yang Y; Sepulveda H; Shi W; Hwang I; Peterson PA; Jackson MR; Sprent J; Cai Z Science; 1999 Oct; 286(5441):952-4. PubMed ID: 10542149 [TBL] [Abstract][Full Text] [Related]
47. Efficacy of a Virus-Like Nanoparticle As Treatment for a Chronic Viral Infection Is Hindered by IRAK1 Regulation and Antibody Interference. Chartrand K; Lebel MÈ; Tarrab E; Savard P; Leclerc D; Lamarre A Front Immunol; 2017; 8():1885. PubMed ID: 29354118 [TBL] [Abstract][Full Text] [Related]
48. Role of non-classical T cells in skin immunity. Park JS; Kim JH Mol Immunol; 2018 Nov; 103():286-292. PubMed ID: 30343117 [TBL] [Abstract][Full Text] [Related]
49. Pharmacological interaction of drugs with immune receptors: the p-i concept. Pichler WJ; Beeler A; Keller M; Lerch M; Posadas S; Schmid D; Spanou Z; Zawodniak A; Gerber B Allergol Int; 2006 Mar; 55(1):17-25. PubMed ID: 17075282 [TBL] [Abstract][Full Text] [Related]
50. Crystal structure of the coat protein of the flexible filamentous papaya mosaic virus. Yang S; Wang T; Bohon J; Gagné MÈ; Bolduc M; Leclerc D; Li H J Mol Biol; 2012 Sep; 422(2):263-73. PubMed ID: 22659319 [TBL] [Abstract][Full Text] [Related]
51. Molecular Modelling and Insilico Engineering of PapMV-CP Towards Display and Development of Capripox Viral Like Particles Based on Immunogenic P32 Envelop Protein is the Homologous of the Vaccinia-Viral H3L Gene: An Insilico Approach. Kumar BK; Kumar KM; Reddy GBM; Abraham S; Yogisharadhya R; Prashantha CN Int J Pept Res Ther; 2020; 26(4):2155-2167. PubMed ID: 32421016 [TBL] [Abstract][Full Text] [Related]
52. The F13 residue is critical for interaction among the coat protein subunits of papaya mosaic virus. Laliberté Gagné ME; Lecours K; Gagné S; Leclerc D FEBS J; 2008 Apr; 275(7):1474-1484. PubMed ID: 18312419 [TBL] [Abstract][Full Text] [Related]
53. Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. Capasso C; Hirvinen M; Garofalo M; Romaniuk D; Kuryk L; Sarvela T; Vitale A; Antopolsky M; Magarkar A; Viitala T; Suutari T; Bunker A; Yliperttula M; Urtti A; Cerullo V Oncoimmunology; 2016 Apr; 5(4):e1105429. PubMed ID: 27141389 [TBL] [Abstract][Full Text] [Related]
54. How Computational Epitope Mapping Identifies the Interactions between Nanoparticles Derived from Papaya Mosaic Virus Capsid Proteins and Immune System. Zamani-Babgohari M; Hefferon KL; Huang T; AbouHaidar MG Curr Genomics; 2019 Apr; 20(3):214-225. PubMed ID: 31929728 [TBL] [Abstract][Full Text] [Related]
55. Targeting Proteasomes and the MHC Class I Antigen Presentation Machinery to Treat Cancer, Infections and Age-Related Diseases. Rana PS; Ignatz-Hoover JJ; Driscoll JJ Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067336 [TBL] [Abstract][Full Text] [Related]
56. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Pichler WJ Curr Opin Allergy Clin Immunol; 2002 Aug; 2(4):301-5. PubMed ID: 12130944 [TBL] [Abstract][Full Text] [Related]
57. Immortalized B Cells Transfected with mRNA of Antigen Fused to MITD (IBMAM): An Effective Tool for Antigen-Specific T-Cell Expansion and TCR Validation. Wang Z; Zhang T; Anderson A; Lee V; Szymura S; Dong Z; Kuang B; Oh E; Liu J; Neelapu SS; Kwak L; Cha SC Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979775 [TBL] [Abstract][Full Text] [Related]
58. Selective proteasome inhibitors: modulators of antigen presentation? Groettrup M; Schmidtke G Drug Discov Today; 1999 Feb; 4(2):63-71. PubMed ID: 10234158 [TBL] [Abstract][Full Text] [Related]
59. MHC tetramer technology: Exploring T cell biology in health and disease. Tiwari R; Singh VK; Rajneesh ; Kumar A; Gautam V; Kumar R Adv Protein Chem Struct Biol; 2024; 140():327-345. PubMed ID: 38762273 [TBL] [Abstract][Full Text] [Related]
60. Membrane-coated nanoparticles for direct recognition by T cells. Li F; Li F; Urie R; Bealer E; Ruiz RO; Saito E; Turan A; Yolcu E; Shirwan H; Shea LD Biotechnol Bioeng; 2023 Mar; 120(3):767-777. PubMed ID: 36515455 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]